The therapeutic effectiveness of desmopressin (DDAVP) was evaluated in 40 children. The protocol consisted of 20 and 30 mcg administrations in a pattern including observation, placebo, and treatment for 6 weeks. There was a prompt response to treatment, and success was achieved in nearly 90% of cases. This, coupled with the tolerability of DDAVP and the complete absence of side-effects, indicates that it is both effective and safe for the management of enuresis.
|Translated title of the contribution||Desmopressin (DDAVP): A new solution to the treatment of enuresis|
|Number of pages||8|
|Publication status||Published - 1982|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health